US-based CereVasc has formed a partnership with LianMedical to introduce its eShunt System and related products in China.
The deal will also allow the supply of the products to patients and providers in Macaw, Hong Kong and Taiwan.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The eShunt System consists of an endovascularly implantable cerebral spinal fluid shunt and associated delivery components, which will help avoid the need for general anaesthesia, invasive surgery, extended hospitalisation and post-procedure pain management.
It is intended for the significant reduction of failures linked to ventriculoperitoneal shunt systems such as catheter obstruction, over-drainage and infection.
The system provides percutaneous transvenous-transdural access to the central nervous system to enable minimally invasive treatment for communicating hydrocephalus.
It is currently under investigation and not available for sale within or outside the US.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCereVasc president and CEO Dan Levangie said: “We are very excited by the opportunity for our products to improve the standard of care for patients with hydrocephalus in these territories and believe we have identified the ideal partner in LianMedical to support these expansion efforts.”
LianMedical CEO Luxin Wang said: “There is a significant unmet clinical need in hydrocephalus treatment in Asia.
“The eShunt System is an innovation that can potentially revolutionise the standard of care and benefit thousands of patients. We are excited to partner with Dan and his team to capitalise on this significant opportunity.”
